Show simple item record

dc.contributor.authorHiukka, A.
dc.contributor.authorLeinonen, E.
dc.contributor.authorJauhiainen, M.
dc.contributor.authorSundvall, J.
dc.contributor.authorEhnholm, C.
dc.contributor.authorKeech, A.
dc.contributor.authorTaskinen, M.
dc.contributor.authorHamilton-Craig, Ian
dc.contributor.authoret al.
dc.date.accessioned2017-05-03T13:55:22Z
dc.date.available2017-05-03T13:55:22Z
dc.date.issued2007
dc.identifier.issn0012186X
dc.identifier.doi10.1007/s00125-007-0751-8
dc.identifier.urihttp://hdl.handle.net/10072/32152
dc.description.abstractAims/hypothesis: Low HDL-cholesterol (HDL-C) is frequently accompanied by high triacylglycerol levels in diabetic dyslipidaemia, increasing the risk of CHD. In the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, fenofibrate treatment lowered triacylglycerol levels, but the initial 5% increase in HDL-C attenuated over 5 years. We explored the changes in VLDL and HDL subspecies during fenofibrate treatment in a statin-free FIELD cohort. Methods: We randomised 171 participants with type 2 diabetes mellitus, who had been recruited to the FIELD study in Helsinki, to micronised fenofibrate (200 mg/day) or placebo in double-blind study design. VLDL and HDL subspecies were separated by ultracentrifugation at baseline and at the second and fifth year. Apolipoprotein (apo)A-I and apoA-II were measured by immunoturbidometric methods and lipoprotein (Lp)A-I and LpAI-AII particles by differential immunoassay. Results: Fenofibrate reduced plasma triacylglycerol levels by 26%, resulting from a marked reduction in VLDL1 triacylglycerol (0.62 vs 0.29 mmol/l, p<0.001). Fenofibrate caused an increase in LDL size (?0.80 nm, p<0.001). HDL-C was similar between the groups. HDL2-C was decreased by fenofibrate (-27.5% at 5th year, p<0.001) and HDL3-C increased (13.0% at 5th year, p<0.001). Fenofibrate had no effect on apoA-I, whereas apoA-II increased. Thus, LpA-I decreased while LpAI-AII increased. Activities of cholesteryl ester transfer protein, phospholipids transfer protein and lecithin:cholesterylacyl transferase were unchanged by fenofibrate. High homocysteine levels were associated with a slight decrease in HDL-C and apoA-I. Conclusions/interpretation: Fenofibrate markedly reduced large VLDL particles and produced a clear shift in HDL subspecies towards smaller particles. The HDL3-C increase in conjunction with unchanged apoA-II levels is a dilemma with regard to cardiovascular disease.
dc.description.peerreviewedYes
dc.description.publicationstatusYes
dc.languageEnglish
dc.language.isoeng
dc.publisherSpringer
dc.publisher.placeGermany
dc.relation.ispartofstudentpublicationN
dc.relation.ispartofpagefrom2067
dc.relation.ispartofpageto2075
dc.relation.ispartofissue10
dc.relation.ispartofjournalDiabetologia
dc.relation.ispartofvolume50
dc.rights.retentionY
dc.subject.fieldofresearchClinical Sciences
dc.subject.fieldofresearchPaediatrics and Reproductive Medicine
dc.subject.fieldofresearchPublic Health and Health Services
dc.subject.fieldofresearchcode1103
dc.subject.fieldofresearchcode1114
dc.subject.fieldofresearchcode1117
dc.titleLong-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.date.issued2014-10-10T01:55:45Z
gro.hasfulltextNo Full Text
gro.griffith.authorHamilton-Craig, Ian


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record